We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
102 hedge funds and large institutions have $92.2M invested in Puma Biotechnology in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more call options, than puts
Call options by funds: $725K | Put options by funds: $519K
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
4.6% less ownership
Funds ownership: 78.88% → 74.27% (-4.6%)
11% less funds holding
Funds holding: 115 → 102 (-13)
39% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 33
59% less capital invested
Capital invested by funds: $226M → $92.2M (-$134M)
Holders
102
Holders Change
-13
Holders Change %
-11.3%
% of All Funds
1.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
38
Reduced
34
Closed
33
Calls
$725K
Puts
$519K
Net Calls
+$206K
Net Calls Change
-$231K
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$6.4M |
| 2 |
EP
Eversept Partners
New York
|
+$3.12M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.98M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.94M |
| 5 |
Walleye Capital
New York
|
+$1.75M |
